AVITA Medical Inc RCEL
NASDAQ · United States · Health Technology
$12.72+0.71 (+5.91%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
AVITA Medical’s updated valuation work now points to a fair value of $12.29, compared with the prior $11.06, which gives you a fresh reference point for where analysts see the stock’s central value today. The shift lines up with commentary that has turned more constructive after the PermeaDerm I data, recent quarterly results, and a view that current evidence and reimbursement trends support a higher fair valuation range. Read on to see what is driving this evolving narrative and how to track...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.